skip navigation
A B C D E F G H I J K L M N O P Q

Test Identifier Information

 
Registration CodePNP
Method

RIA-Uniq P3NP Orion Diagnostica kit

Diagnostic Use / Indications

Screening for methotrexate-induced liver fibrosis in patients with skin disease e.g., psoriasis.

P3 NP is not organ specific and does not reflect earlier liver damage - it reflects fibrogenesis.

A study published in the British Journal of Dermatology (2001:143;100-103), concluded that as long as P3 NP was consistently normal in serial investigations there was minimal risk of developing substantial hepatic necrosis.
 

External Price$66.74(Exclusive of GST)
  

Specimen Collection

 
Patient SpecimenClotted blood(Red), Serum only
Paediatric Specimen0.5 mL serum (Red)
Sample Delivery to LabAmbient
  

Instructions for Referral to CHLabs

 
Aliquot Instructions1 mL serum separate within 1-2 hrs Only Serum, other sample types are unsuitable
Aliquot Transport to CHLfrozen
  

CHLabs Laboratory

 
DepartmentBiochemistry - Specialist
Contact Details Email Email
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Contact Phone Number03 364 0326 x 80326
Test AvailabilityPerformed as a batch of 40 samples
Turnaround Time1-3 weeks
Reference Interval

Ref range 2.3 - 6.4 ug/L

Interpretation

According to the Manchester protocol (Br J Derm 2005; 152:444-50), P3NP should be monitored every 2-3 months during continued methotrexate treatment. Considerations for liver biopsy include P3NP above 8.0 ug/L on the pre-treatment sample or on two consecutive samples or P3NP above 4.2 ug/L in at least three samples over a 12 month period. Note that P3NP is a marker of scar formation and transient elevations may be seen with acute tissue damage ( recommend follow up after 3 months) or persistently in other chronic fibrotic conditions ( eg myelofibrosis). It is not intended for use in non-adults.

 

Delphic Number Test Number4758

CHL Follow us on Facebook